Institutional members access full text with Ovid®

Share this article on:

Recent trials in immunosuppression and their consequences for current therapy

Wohlfahrtova, Marianaa,b; Viklicky, Ondreja,b

Current Opinion in Organ Transplantation: August 2014 - Volume 19 - Issue 4 - p 387–394
doi: 10.1097/MOT.0000000000000093
RENAL TRANSPLANTATION: Edited by Uwe Heemanns

Purpose of review Although the scarcity of clinical trials with de-novo immunosuppression has been typical over the last 2 years, several attempts have been made in drug conversion, dosing optimization, and bioequivalence. On the basis of recent clinical and animal studies, future directions of management and treatment are outlined.

Recent findings Studies with new tacrolimus formulations showed better bioavailability and lower doses, which might translate into less toxicity. The long-term results of studies with costimulation blockade confirmed their safety and efficacy. Calcineurin inhibitor (CNI)-free regimens based on mTOR inhibitors were shown to be associated with increased risk of the humoral response. Therefore, ongoing trials are predominantly designed to minimize calcineurin inhibitor dose only. Biologics, such as B-cell-specific agents (bortezomib and rituximab) and complement inhibitors (eculizumab) used to treat antibody-mediated rejection, recurrence of glomerulonephritis, are shifted to more preventive applications. The pretransplant quantification of alloreactive memory/effector T cell response may help to better stratify a patient's immunologic risk and allow for drug minimization.

Summary Despite clinical trials with innovative protocols with already established agents, tacrolimus-based and induction-based protocols have been shown to be the mainstay of immunosuppressive regimens. In the future, research aims to focus on biomarker-driven immunosuppression and cell therapy approaches.

aDepartment of Nephrology, Transplant Centre

bTransplant Laboratory, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

Correspondence to Ondrej Viklicky, MD, PhD, Department of Nephrology, Transplant Centre, Institute for Clinical and Experimental Medicine, Videnska 1958/9, 14021 Prague 4, Czech Republic. Tel: +420 23605 4110; fax: +420 23605 3168; e-mail: ondrej.viklicky@ikem.cz

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins